AN2025 is an oral pan-P13K inhibitor that targets all class I P13K and is active in both hematologic malignancies and solid tumors, which has received a Fast-Track designation and initiated the phase III clinical study from FDA.
Being studied as a potential combination therapy with pactitaxel in recurrent or metastatic neck squamous cell carcinoma (HNSCC), it has shown promising efficacy in combination with paclitaxel.
Head and Neck Squamous Cell Carcinoma (HNSCC)
Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of tumors, including neck tumor, otolaryngology tumor and oral and maxillofacial tumor. HNSCC is the 8th leading cancer by incidence worldwide and constitutes 90% of all head and neck cancers.
Although anti-PD-(L)1 therapy has been approved by the FDA and EMA for the treatment of recurrent or metastatic HNSCC, the response rate of listed PD-(L)1 varieties is lower than 20%. There is still a large unmet medical need for the treatment of HNSCC with no response to PD-(L)1.